6. Actavis

Total: $250.5 million
TV: $116.6 million
Magazine: $129.3 million
Newspaper: $4.5 million
Radio: $35,900

Actavis ($ACT) is the only pharma company in the top 10 that didn't spend the bulk of its budget on TV ads. Instead, the Dublin-based drugmaker, which recently completed its $70.5 billion acquisition of Allergan and is awaiting shareholder approval of an official name change to Allergan, spent more than half of its budget (52%) on magazine advertising.

Allergan's well-known cosmetic pharmaceutical brand Botox--also approved for medical uses such as migraines, muscle spasms and incontinence--was well-represented in both TV and magazine advertising across indications. So was chronic dry eye treatment Restasis and injectable Juvederm. Meanwhile, Actavis' irritable bowel med Linzess, and its illustrative twisted blue rope over bare stomachs, became a familiar advertising image in 2014, along with oral contraceptive Lo Loestrin magazine ads.

The combined company Actavis/Allergan is expected to generate $23 billion in revenues this year, according to an Actavis press release.

For more:
Actavis CEO: We may be big, but we don't want to be Big Pharma
Actavis revs up new commercial team for post-Allergan-merger sales race
Analysts: Actavis-Allergan deal could create a marketing superpower
Allergan's pipeline in a drug, Botox could keep new marketing twists coming

6. Actavis
Read more on

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.